Skip to main content

Clinical trial D-FR-01087-001

An international multi-center, open-label radioactivity escalation study to evaluate the safety, tolerability, biodistribution, and preliminary anti-tumor activity of 177Lu-3BP-227 for therapy in previously treated patients with advanced gastrointestinal cancers expressing neurotensin 1 receptors

Organ Germ cell tumors
Trial status Trial closed
Trial type
Interventional with experimental drug
Phase Trial phase 1/2
Academic trial Non
Sponsor Ipsen
EudraCT Identifier 2017-001263-20
Inclusion criteria *NTSR1 expression*Measureable disease RECIST 1.1
Last update